Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
1. Stifel upgraded EW from Hold to Buy, boosting price target to $90. 2. Analyst cites TAVR growth re-acceleration supported by physician feedback. 3. FDA may expand TAVR label for severe aortic stenosis by mid-2025. 4. Sale of Critical Care business may elevate Edwards' valuation. 5. Operating margin expansion anticipated starting in 2026 boosts investor confidence.